Article

Nidek sister companies consolidate U.S. business activities

Nidek Co. Ltd.'s two wholly owned subsidiaries-Nidek Technologies America (NTA), Greensboro, NC, and Nidek Inc., Fremont, CA-will merge and consolidate business activities in the U.S. market, effective April 1, 2006.

The Gamagori, Japan-based company said it expects this action to harmonize and harness commercial synergies further and to solidify Nidek's U.S. business. In addition, the transaction is a strategic move to further product marketing/distribution goals and objectives in the United States, according to Nidek.

NTA's focus is on commercializing advanced ophthalmic diagnostic instrumentation for corneal and retinal applications, while the focus of Nidek Inc. is the U.S. sales and marketing organization.

"Bringing the two groups together will allow Nidek to offer one source for its advanced diagnostics and surgical ophthalmic instrumentation to the vision-care professional in the United States," said Hideo Ozawa, president and founder of Nidek Co. Ltd. "Additionally, through this consolidation, we aim to streamline business operations-sales, marketing, accounting, and customer and product service-enabling Nidek to focus and achieve its short- and long-term goals and objectives."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.